Literature DB >> 23876844

Hepatosplenic γδ T-cell lymphoma: an overview.

Koppany Visnyei1, Michael L Grossbard, Ilan Shapira.   

Abstract

Peripheral T-cell lymphomas are a heterogeneous group of lymphoid malignancies. Among these, hepatosplenic γδ T-cell lymphoma (HTCL) represents an aggressive and treatment-resistant subgroup for which new avenues of treatment are critically needed. HTCL is characterized by primary extranodal distribution of the malignant cells with typical intrasinusoidal infiltration of the liver, spleen, and bone marrow, which results in hepatosplenomegaly and peripheral blood cytopenias. Another characteristic feature is the expression of γδ T-cell receptors. HTCL exhibits a rapid progressive course and an extremely poor response to currently known therapeutic strategies, with a 5-year overall survival rate of only 7%. In this review, we discuss the clinical, pathologic, and molecular characteristics of this disease, along with the challenges that are associated with its diagnosis and treatment.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Allogeneic transplantation; Autologous transplantation; CHOP; Hyper-CVAD; T-cell receptor; TCR

Mesh:

Substances:

Year:  2013        PMID: 23876844     DOI: 10.1016/j.clml.2013.03.011

Source DB:  PubMed          Journal:  Clin Lymphoma Myeloma Leuk        ISSN: 2152-2669


  8 in total

1.  Clinical features and treatment outcomes of 14 patients with hepatosplenic γ δ T-cell lymphoma.

Authors:  Qian Wang; Yibin Jiang; Qian Zhu; Yishan Duan; Xiaochen Chen; Ting Xu; Zhengming Jin; Caixia Li; Depei Wu; Haiwen Huang
Journal:  J Cancer Res Clin Oncol       Date:  2021-04-15       Impact factor: 4.553

2.  Incidence and outcomes of rare T cell lymphomas from the T Cell Project: hepatosplenic, enteropathy associated and peripheral gamma delta T cell lymphomas.

Authors:  Francine M Foss; Steven M Horwitz; Monica Civallero; Monica Bellei; Luigi Marcheselli; Won Seog Kim; Maria E Cabrera; Ivan Dlouhy; Arnon Nagler; Ranjana H Advani; Emanuela A Pesce; Young-Hyeh Ko; Silvia Montoto; Carlos Chiattone; Alison Moskowitz; Michele Spina; Marina Cesaretti; Irene Biasoli; Massimo Federico
Journal:  Am J Hematol       Date:  2019-11-25       Impact factor: 10.047

3.  18F-FDG PET/CT findings in hepatosplenic Gamma-Delta T-cell lymphoma: case reports and review of the literature.

Authors:  Michael W Cho; Bennett B Chin
Journal:  Am J Nucl Med Mol Imaging       Date:  2018-04-25

4.  Hepatosplenic T cell lymphoma: a unifying entity in a patient with hemolytic anemia, massive splenomegaly, and liver dysfunction.

Authors:  Marianna Mavilia; Agnes McAuliffe; Safina Hafeez; Haleh Vaziri
Journal:  Clin J Gastroenterol       Date:  2018-05-15

Review 5.  Primary spleen extranodal NK/T cell lymphoma, nasal type, with bone marrow involvement and CD30 positive expression: a case report and literature review.

Authors:  Qinghua Cao; Yan Huang; Ziyin Ye; Ni Liu; Shuhua Li; Tingsheng Peng
Journal:  Diagn Pathol       Date:  2014-09-03       Impact factor: 2.644

6.  Four hepatosplenic T-cell lymphoma cases of Japanese patients.

Authors:  Hidetsugu Kawai; Hiromichi Matsushita; Ken Ohmachi; Minoru Kojima; Shinichiro Machida; Yoshiaki Ogawa; Hiroshi Kawada; Naoya Nakamura; Kiyoshi Ando
Journal:  Leuk Res Rep       Date:  2015-12-15

7.  Successful Bridging Chemotherapy with Gemcitabine, Carboplatin, and Dexamethasone before Unrelated Stem Cell Transplantation for Hepatosplenic T-cell Lymphoma.

Authors:  Marika Okuni; Kimikazu Yakushijin; Keiichiro Uehara; Hiroya Ichikawa; Hirotaka Suto; Akiko Hashimoto; Yasuhiro Tanaka; Isaku Shinzato; Rina Sakai; Yu Mizutani; Shigeki Nagao; Keiji Kurata; Seiji Kakiuchi; Yoshiharu Miyata; Yumiko Inui; Yasuyuki Saito; Shinichiro Kawamoto; Katsuya Yamamoto; Mitsuhiro Ito; Hiroshi Matsuoka; Hironobu Minami
Journal:  Intern Med       Date:  2018-11-19       Impact factor: 1.271

8.  Bone marrow particle enrichment analysis for the laboratory diagnosis of multiple myeloma: A case study.

Authors:  Congming Zhang; Yanan Zhang
Journal:  J Clin Lab Anal       Date:  2020-06-16       Impact factor: 2.352

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.